Boston Scientific (NYSE:BSX) last week escaped a long-running royalties dispute with coronary stent pioneer Dr. David Jang that could have cost it $200 million.
Judge Virginia Phillips of the U.S. District Court for Central California found Sept. 29 that Jang’s claims covered previous patents, triggering the ensnarement defense barring a patentee from asserting a scope of equivalency that would encompass, or ensnare, the prior art.
The case dates back to 1999, when Jang won approval from the U.S. Patent & Trademark Office for a stent design featuring lateral struts.
Help employers find you! Check out all the jobs and post your resume.
Judge Virginia Phillips of the U.S. District Court for Central California found Sept. 29 that Jang’s claims covered previous patents, triggering the ensnarement defense barring a patentee from asserting a scope of equivalency that would encompass, or ensnare, the prior art.
The case dates back to 1999, when Jang won approval from the U.S. Patent & Trademark Office for a stent design featuring lateral struts.
Help employers find you! Check out all the jobs and post your resume.
